Convatec (LSE:CTEC) looks uncovered on one widely quoted measure, even as the medical products group raises its payout at a steady pace. The explanation lies largely in a non-cash writedown rather than in any shortage of cash. With a 10-month trading update due on 18 November, the numbers deserve a closer reading.

The Dividend at a glance

As of 7 October 2026, Convatec's annual dividend was 5.4p per share and its latest payment was 1.6p. The trailing 12-month Yield and the indicated yield were both 2.6%, which suggests little difference between what has been paid and what the current run rate implies.

Year-on-year dividend growth was 6.2%, although the most recent interim rose faster. In August the board set the first-half payment at 2.166 US cents, an increase of about 15%. The company had to correct a small error in its original disclosure, which had shown a slightly different figure in one table, and the corrected amount matches the 1.6p once converted. Like several large London-listed groups, Convatec reports and declares in US dollars, so the pence amount paid to UK holders depends on the Exchange Rate applied.

Reading the 121% payout

The trailing Payout Ratio of 121.1% would, taken at face value, mean Convatec is distributing more than it earns. A figure above 100% is normally a warning sign, because a dividend that exceeds profits must eventually be funded from reserves or debt.

Here the context matters. In the six months to 30 June, reported operating profit fell 36.1% to $115m, weighed down by a $69m non-cash Impairment on InnovaMatrix assets. Reported Diluted Earnings per Share dropped 47.8% to 2.7 cents. Adjusted diluted earnings per share, by contrast, rose 6.3% to 8.5 cents, about four times the interim dividend. The headline ratio therefore overstates the strain, since an impairment reduces reported profit without consuming cash.

It does not remove every concern. Writedowns reflect Capital that has failed to earn its expected return, and investors will want to see reported profit move closer to the adjusted figure before treating the gap as purely cosmetic. Adjusted measures also leave out certain costs by design, so they are best read alongside the statutory figures rather than instead of them.

How the payout is built

Payout ratio is calculated by dividing dividends per share by earnings per share, and the answer depends entirely on which earnings are chosen. A trailing ratio uses the latest 12 months of reported profit, which in this case includes the impairment. An adjusted ratio uses profit before such items and gives a very different picture, with the Interim Dividend covered roughly four times by adjusted earnings per share for the half.

The company has also pointed to its cash generation as the real support for distributions. A medical technology group that sells continence, wound and ostomy care products tends to produce steady, repeat revenue, because patients need supplies on an ongoing basis. That kind of recurring Demand makes Cash Flow more predictable than in many cyclical industries, and it is the reason a non-cash charge matters less to dividend capacity than it would to a stock whose cash flow is volatile.

Streaks and Shareholder returns

Convatec has paid dividends for nine consecutive years and has increased them for only two. That places it some way short of the FTSE 100's long-established income names, and the short growth run suggests the current pace of increases is relatively new.

Dividends are also only part of the return. Alongside its interims, the group launched a $200m share buyback, due to be completed by 31 December, following a $300m programme finished in 2025. Those purchases have come while Leverage edged up, with net Debt at 2.3 times adjusted EBITDA at the end of June against 2.0 times at the end of 2025. Management expects to return to about 2.0 times by the year end, a target that the update may help investors assess.

A short growth record has one advantage: the board is not defending a decades-long sequence and can therefore set the dividend in line with earnings and cash needs. At the same time, shareholders have had less time to judge how management would respond to a sustained downturn. The combination of Buybacks and dividends suggests confidence in cash generation, but the rise in leverage over the first half shows that the Balance Sheet is being asked to do more work than before, which is why the year-end target is worth following closely.

Trading backdrop

Convatec confirmed its 2026 guidance in August: organic Revenue growth of 5.5% to 6.5% excluding InnovaMatrix, an adjusted Operating Margin of at least 23% and double-digit growth in adjusted earnings per share. First-half revenue rose 4.4% to $1.232bn, leaving a firmer second half to deliver.

For a Business with Convatec (LSE:CTEC)'s profile, the margin target matters as much as revenue, since it determines how much of each additional dollar of sales reaches earnings and, ultimately, the dividend. The first half delivered an adjusted margin of 21.2%, so the second half needs a clear step up.

What to watch on 18 November

The main test is whether Convatec reiterates its full-year range and shows the expected acceleration in the second half. Margin progress towards 23% matters too, given that the first half delivered 21.2%. Income investors should also watch for any update on leverage and on further InnovaMatrix pressures, ahead of preliminary results due on 23 February 2027.

Leverage deserves particular attention, because buybacks and dividends compete for the same cash. If net debt tracks towards 2.0 times EBITDA as planned, the board retains flexibility. If it does not, the company may need to choose between further share repurchases and the pace of dividend increases, which would be relevant to anyone holding Convatec (LSE:CTEC) for its income.